← Trials/Trial dossier/NCT00809510

TerminatedPhase 2

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Lead sponsor

Abbott

Asset

ABT-089

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age 55-90

Primary endpoint

•Safety Assessments

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDM10-745

NCT IDNCT00809510

Timeline

Milestones

Study first posted2008-12-17estimated

Study start2009-01 (month precision)

Primary completion2009-06actual (month precision)

Last update posted2011-09-02estimated

Assets

Drug assets

ABT-089

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•The subject was randomized into Study M06-876 and completed the study.

•The subject must remain on the same dose of AChEI that was used during the M06-876 study.

•The subject is in general good health, as judged by the investigator

Exclusion criteria

•The subject is currently, or plans to participate in another experimental study during the course of this trial.

•The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Safety / tolerability / PK

Global cognition

1 endpoint

Secondary/protocol endpoint

ADAS-Cog, CIBIC-plus, MMSE, QoL-AD

Time frame:Month 1, 2, 4, 6

ADAS-Cog

descriptive

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)

Time frame:Month 1, 2, 4, 6

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.